Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

ClinicalTrials.gov ID: NCT02978222

Public ClinicalTrials.gov record NCT02978222. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy

Study identification

NCT ID
NCT02978222
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Marker Therapeutics, Inc.
Industry
Enrollment
120 participants

Conditions and interventions

Interventions

  • FRα peptide plus Adjuvant (GM-CSF) Biological
  • Adjuvant (GM-CSF) Alone Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 19, 2017
Primary completion
Jan 14, 2020
Completion
Jan 14, 2020
Last update posted
Dec 14, 2022

2017 – 2020

United States locations

U.S. sites
18
U.S. states
14
U.S. cities
17
Facility City State ZIP Site status
UAB Gynecology Oncology Birmingham Alabama 35233
Mayo Clinic Cancer Center Phoenix Arizona 85054
Women's Cancer Research Foundation Newport Beach California 92663
The Stamford Hospital/Bennett Cancer Center Stamford Connecticut 06904
Mayo Clinic Florida Jacksonville Florida 32224
Mt. Sinai Comprehensive Cancer Center Miami Beach Florida 33140
Moffitt Cancer Center Tampa Florida 33612
Florida Cancer Specialist West Palm Beach Florida 33401
Mayo Clinic Rochester Rochester Minnesota 55905
Research Partners Jackson Mississippi 39202
MidAmerica Division, Inc. c/o Research Medical Center Kansas City Missouri 64132
University Of New Mexico Comprehensive Cancer Center Albuquerque New Mexico 87102
Memorial Sloan Kettering Cancer Center New York New York 10065
Hematology/Oncology Lenox Hill Hospital New York New York 10075
Duke University Medical Center Durham North Carolina 27710
OHSU Portland Oregon 97239
Abington Memorial Hospital Abington Pennsylvania 19001
Tennessee Oncology/Sarah Cannon Research Institute Nashville Tennessee 37203

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02978222, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 14, 2022 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02978222 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →